Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

This study has been completed.
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: February 19, 2004
Last updated: October 14, 2016
Last verified: October 2016